New paradigms for treatment development

被引:12
作者
Stover, Ellen L.
Brady, Linda
Marder, Stephen R.
机构
[1] Univ Calif Los Angeles, Semel Inst Neurosci, Los Angeles, CA 90073 USA
[2] Desert Pacific Mental Illness Res Educ & Clin Ctr, Los Angeles, CA 90073 USA
[3] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA
[4] NIMH, Bethesda, MD 20892 USA
关键词
schizophrenia; treatment; pharmacology;
D O I
10.1093/schbul/sbm085
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Wayne Fenton believed that government-particularly National Institute of Mental Health (NIMH)-could play a critical role in addressing important public health problems where the current system of treatment development was inadequate. Earlier experiences in HIV/AIDS convinced him and others that the NIMH can effectively facilitate the rapid development of new research in critical areas. This report will demonstrate how the work of Fenton and others brought together representatives from industry, government, and academia to address issues that included new preclinical approaches to drug development and defining new therapeutic targets in schizophrenia. An initiative to facilitate the development of new pharmacological agents to address the cognitive impairments in schizophrenia-titled Measurement and Treatment Research to Improve Cognition in Schizophreniaor MATRICS-is used as an example of a new paradigm for treatment development.
引用
收藏
页码:1093 / 1099
页数:7
相关论文
共 25 条
  • [1] Assessment of community functioning in people with schizophrenia and other severe mental illnesses: A white paper based on an NIMH-sponsored workshop
    Bellack, Alan S.
    Green, Michael F.
    Cook, Judith A.
    Fenton, Wayne
    Harvey, Philip D.
    Heaton, Robert K.
    Laughren, Thomas
    Leon, Andrew C.
    Mayo, Donna J.
    Patrick, Donald L.
    Patterson, Thomas L.
    Rose, Andrew
    Stover, Ellen
    Wykes, Til
    [J]. SCHIZOPHRENIA BULLETIN, 2007, 33 (03) : 805 - 822
  • [2] Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia
    Carter, CS
    [J]. SCHIZOPHRENIA BULLETIN, 2005, 31 (04) : 810 - 815
  • [3] COUTINHO R, 2000, AIDS S2, V14, P1
  • [4] Mood disorders: cardiovascular and diabetes comorbidity
    Fenton, Wayne S.
    Stover, Ellen S.
    [J]. CURRENT OPINION IN PSYCHIATRY, 2006, 19 (04) : 421 - 427
  • [5] New approaches to measurement and treatment research to improve cognition in schizophrenia
    Geyer, MA
    Heinssen, R
    [J]. SCHIZOPHRENIA BULLETIN, 2005, 31 (04) : 806 - 809
  • [6] Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects
    Geyer, MA
    Tamminga, CA
    [J]. PSYCHOPHARMACOLOGY, 2004, 174 (01) : 1 - 2
  • [7] Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
    Green, MF
    Nuechterlein, KH
    Gold, JM
    Barch, DM
    Cohen, J
    Essock, S
    Fenton, WS
    Frese, F
    Goldberg, TE
    Heaton, RK
    Keefe, RSE
    Kern, RS
    Kraemer, H
    Stover, E
    Weinberger, DR
    Zalcman, S
    Marder, SR
    [J]. BIOLOGICAL PSYCHIATRY, 2004, 56 (05) : 301 - 307
  • [8] Green MF, 1996, AM J PSYCHIAT, V153, P321
  • [9] Harvey PD, 2004, J CLIN PSYCHIAT, V65, P361
  • [10] HEGARTY JD, 1994, AM J PSYCHIAT, V151, P1409